{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=C3+Glomerulopathy", "query": { "condition": "C3 Glomerulopathy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=C3+Glomerulopathy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T06:45:01.141Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04572854", "title": "Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "C3G", "IC-MPGN", "Renal Transplant", "Complement 3 Glomerulopathy", "Complement 3 Glomerulopathy (C3G)", "Dense Deposit Disease (DDD)", "Membranoproliferative Glomerulonephritis", "Membranoproliferative Glomerulonephritis (MPGN)", "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)", "C3 Glomerulopathy", "C3 Glomerulonephritis", "Complement 3 Glomerulonephritis" ], "interventions": [ { "name": "Pegcetacoplan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apellis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-09-07", "completion_date": "2026-01-20", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04572854" }, { "nct_id": "NCT05067127", "title": "Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "C3G", "IC-MPGN", "C3 Glomerulopathy", "C3 Glomerulonephritis", "Complement 3 Glomerulopathy", "Complement 3 Glomerulopathy (C3G)", "Complement 3 Glomerulonephritis", "Dense Deposit Disease", "DDD", "Membranoproliferative Glomerulonephritis", "Membranoproliferative Glomerulonephritis (MPGN)", "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)" ], "interventions": [ { "name": "Pegcetacoplan", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Apellis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 124, "start_date": "2021-11-12", "completion_date": "2025-01-14", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05067127" }, { "nct_id": "NCT05809531", "title": "An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "C3G", "IC-MPGN", "C3 Glomerulopathy", "C3 Glomerulonephritis", "Complement 3 Glomerulopathy", "Complement 3 Glomerulopathy (C3G)", "Complement 3 Glomerulonephritis", "Dense Deposit Disease", "DDD", "Membranoproliferative Glomerulonephritis", "Membranoproliferative Glomerulonephritis (MPGN)", "Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)" ], "interventions": [ { "name": "Pegcetacoplan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apellis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": "2023-05-29", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 12, "location_summary": "Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainsville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05809531" }, { "nct_id": "NCT03955445", "title": "Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "C3 Glomerulopathy", "Immune-complex-membranoproliferative Glomerulonephritis" ], "interventions": [ { "name": "LNP023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "12 Years to 100 Years" }, "enrollment_count": 225, "start_date": "2019-10-03", "completion_date": "2036-05-30", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 5, "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03955445" }, { "nct_id": "NCT04817618", "title": "Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "C3G" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "iptacopan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "12 Years to 60 Years" }, "enrollment_count": 98, "start_date": "2021-07-28", "completion_date": "2027-01-29", "has_results": false, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 13, "location_summary": "Aurora, Colorado • Miami, Florida • Lawrenceville, Georgia + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04817618" }, { "nct_id": "NCT03832114", "title": "Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glomerulonephritis" ], "interventions": [ { "name": "LNP023", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-02-20", "completion_date": "2021-04-23", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT03832114" }, { "nct_id": "NCT03316521", "title": "First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Complement Mediated Diseases" ], "interventions": [ { "name": "AMY-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amyndas Pharmaceuticals S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "MALE", "summary": "18 Years to 60 Years · Male only" }, "enrollment_count": 50, "start_date": "2017-04-24", "completion_date": "2017-11-30", "has_results": false, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 1, "location_summary": "High Point, North Carolina", "locations": [ { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03316521" }, { "nct_id": "NCT06419205", "title": "A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IgA Nephropathy", "Lupus Nephritis (LN)", "C3 (Complement Component 3) Glomerulopathy" ], "interventions": [ { "name": "ADX-097", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Q32 Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-06-27", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 5, "location_summary": "Denver, Colorado • Minneapolis, Minnesota • Las Vegas, Nevada + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06419205" }, { "nct_id": "NCT03095118", "title": "Daratumumab in Treatment of PGNMID and C3 GN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Membranoproliferative Glomerulonephritis" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fernando Fervenza", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2017-09-07", "completion_date": "2020-05-12", "has_results": true, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03095118" }, { "nct_id": "NCT03369236", "title": "A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "C3 Glomerulopathy", "C3 Glomerulonephritis", "Dense Deposit Disease" ], "interventions": [ { "name": "Danicopan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "17 Years to 65 Years" }, "enrollment_count": 13, "start_date": "2018-06-12", "completion_date": "2020-12-18", "has_results": true, "last_update_posted_date": "2022-10-14", "last_synced_at": "2026-05-22T06:45:01.141Z", "location_count": 6, "location_summary": "Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lawrenceville", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03369236" } ] }